Consideration for treatment of upper urinary tract tumors with topical therapy.
The use of topical chemotherapy for the treatment of upper urinary tract urothelial tumors and the selection of patients to receive this treatment remain problematic because of the relatively infrequent occurrence of these tumors compared with similar tumors within the bladder. The lack of clinicopathologic information on upper urinary tract urothelial tumors makes pretherapy diagnosis and clinical staging difficult. In addition, there are problems associated with delivery of the agent, and there is not as yet an effective method of surveillance after treatment. Only continued investigation with endoscopic diagnosis and treatment, as well as longitudinal follow-up, will determine methods of patients selection and the optimal use of topical chemotherapy.
D000287:Administration, Topical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004724:Endoscopy; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D007682:Kidney Pelvis / Q000187:drug effects / Q000473:pathology; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D014513:Ureter / Q000187:drug effects / Q000473:pathology; D014516:Ureteral Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology
D000970:Antineoplastic Agents